ATC code C10
| ATC codes |
|---|
| C Cardiovascular system |
| C01 Cardiac therapy |
| C02 Antihypertensives |
| C03 Diuretics |
| C04 Peripheral vasodilators |
| C05 Vasoprotectives |
| C07 Beta blocking agents |
| C08 Calcium channel blockers |
| C09 Agents acting on the renin-angiotensin system |
| C10 Lipid modifying agents |
|
|
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup C10 is part of the anatomical group C Cardiovascular system.[1]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC10.[2]National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
C10A Lipid modifying agents, plain
C10AA HMG CoA reductase inhibitors
- C10AA01 Simvastatin
- C10AA02 Lovastatin
- C10AA03 Pravastatin
- C10AA04 Fluvastatin
- C10AA05 Atorvastatin
- C10AA06 Cerivastatin
- C10AA07 Rosuvastatin
- C10AA08 Pitavastatin
C10AB Fibrates
- C10AB01 Clofibrate
- C10AB02 Bezafibrate
- C10AB03 Aluminium clofibrate
- C10AB04 Gemfibrozil
- C10AB05 Fenofibrate
- C10AB06 Simfibrate
- C10AB07 Ronifibrate
- C10AB08 Ciprofibrate
- C10AB09 Etofibrate
- C10AB10 Clofibride
- C10AB11 Choline fenofibrate
C10AC Bile acid sequestrants
- C10AC01 Colestyramine
- C10AC02 Colestipol
- C10AC03 Colextran
- C10AC04 Colesevelam
C10AD Nicotinic acid and derivatives
- C10AD01 Niceritrol
- C10AD02 Nicotinic acid
- C10AD03 Nicofuranose
- C10AD04 Aluminium nicotinate
- C10AD05 Nicotinyl alcohol (pyridylcarbinol)
- C10AD06 Acipimox
- C10AD52 Nicotinic acid, combinations
C10AX Other lipid modifying agents
- C10AX01 Dextrothyroxine
- C10AX02 Probucol
- C10AX03 Tiadenol
- C10AX05 Meglutol
- C10AX06 Omega-3-triglycerides
- C10AX07 Magnesium pyridoxal 5-phosphate glutamate
- C10AX08 Policosanol
- C10AX09 Ezetimibe
- C10AX10 Alipogene tiparvovec
- C10AX11 Mipomersen
- C10AX12 Lomitapide
- C10AX13 Evolocumab
C10B Lipid modifying agents, combinations
C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents
- C10BA01 Lovastatin and nicotinic acid
- C10BA02 Simvastatin and ezetimibe
- C10BA03 Pravastatin and fenofibrate
- C10BA04 Simvastatin and fenofibrate
- C10BA05 Atorvastatin and ezetimibe
- C10BA06 Rosuvastatin and ezetimibe
C10BX HMG CoA reductase inhibitors, other combinations
- C10BX01 Simvastatin and acetylsalicylic acid
- C10BX02 Pravastatin and acetylsalicylic acid
- C10BX03 Atorvastatin and amlodipine
- C10BX04 Simvastatin, acetylsalicylic acid and ramipril
- C10BX05 Rosuvastatin and acetylsalisylic acid
- C10BX06 Atorvastatin, acetylsalicylic acid and ramipril
- C10BX07 Rosuvastatin, amlodipine and lisinopril
- C10BX08 Atorvastatin and acetylsalicylic acid
- C10BX09 Rosuvastatin and amlodipine
- C10BX10 Rosuvastatin and valsartan
- C10BX11 Atorvastatin, amlodipine and perindopril
References
- ↑ "ATC/DDD Index 2016: code C10". WHO Collaborating Centre for Drug Statistics Methodology.
- ↑ "ATCvet Index 2016: code QC10". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia - version of the 1/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.